{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:06:31Z","timestamp":1775243191485,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2002,1,12]],"date-time":"2002-01-12T00:00:00Z","timestamp":1010793600000},"content-version":"vor","delay-in-days":187,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,7,9]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Esomeprazole, the <jats:italic>S<\/jats:italic>\u2010isomer of omeprazole, is the first proton pump inhibitor to be developed as an optical isomer. In patients with erosive oesophagitis, esomeprazole has produced significantly greater healing rates and improved symptom resolution vs. omeprazole.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>This study assesses the efficacy of esomeprazole for preventing relapse in patients with healed oesophagitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>In this 6\u2010month US multicentre randomized double\u2010blind placebo\u2010controlled trial, 375 <jats:italic>Helicobacter pylori<\/jats:italic>\u2010negative patients with endoscopically healed oesophagitis received esomeprazole 40\u2003mg, 20\u2003mg, 10\u2003mg, or placebo once daily. The primary efficacy end\u2010point was maintenance of healing at 6\u2003months. Secondary end\u2010points assessed changes in symptoms, and long\u2010term safety and tolerability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Significantly (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.001) more patients remained healed with esomeprazole 40\u2003mg (87.9%), 20\u2003mg (78.7%), or 10\u2003mg (54.2%), than with placebo (29.1%). Relapse, when it occurred, was later with esomeprazole. Sustained resolution of heartburn was observed in the 40\u2003mg and 20\u2003mg groups; there was a high correlation between absence of heartburn and maintenance of healing. Adverse effects were mild, infrequent and not significantly different between groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Esomeprazole is effective and well\u2010tolerated in the maintenance of healing of erosive oesophagitis. Esomeprazole 40\u2003mg and 20\u2003mg offer significant clinical benefit to patients.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01024.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:44:26Z","timestamp":1047354266000},"page":"927-935","source":"Crossref","is-referenced-by-count":97,"title":["The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6\u2010month, randomized, double\u2010blind, placebo\u2010controlled study of efficacy and safety"],"prefix":"10.1111","volume":"15","author":[{"given":"N. B.","family":"Vakil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. D.","family":"Baerg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hamelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.4.481"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199802000-00004"},{"key":"e_1_2_6_4_2","first-page":"211","article-title":"Duodenal ulcer and gastroesophageal reflux disease today: long\u2010term therapy\u2014a sideways glance","volume":"69","author":"Bardhan KD.","year":"1996","journal-title":"Yale J Biol Med"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510263331711"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00381.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(88)90162-X"},{"key":"e_1_2_6_8_2","first-page":"66B","article-title":"Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview","volume":"11","author":"Chiba N.","year":"1997","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.44.2008.S1"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00813.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)82136-8"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00856.x"},{"key":"e_1_2_6_13_2","first-page":"656","article-title":"Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial","volume":"96","author":"Richter JE","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.45.2.172"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1996.v111.pm8698230"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0145-2134(96)00067-1"},{"key":"e_1_2_6_17_2","first-page":"S1","article-title":"Hyperplastic, dysplastic, and neoplastic enterochromafin\u2010like cell proliferation of the gastric mucosa. Classification and histogenesis","volume":"19","author":"Solcia E","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"e_1_2_6_18_2","first-page":"285","article-title":"Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors","volume":"71","author":"Solcia E","year":"1998","journal-title":"Yale J Biol Med"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)82142-3"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)82131-9"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01024.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01024.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01024.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T01:46:08Z","timestamp":1697507168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01024.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7,9]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7,9]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01024.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01024.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7,9]]}}}